Adaptive Biotechnologies (ADPT) Operating Expenses (2018 - 2026)

Adaptive Biotechnologies has reported Operating Expenses for 9 years, with the latest figure at $90.1 million in Q1 2026.

• Quarterly Operating Expenses rose 9.79% year-over-year to $90.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $342.1 million (up 2.77% YoY) and the FY2025 annual result came in at $334.1 million, down 2.17% from the prior year.
• Operating Expenses advanced to $90.1 million in Q1 2026 per ADPT's latest filing, from $84.5 million in the prior quarter.
• Over five years, Operating Expenses peaked at $116.9 million in Q4 2023 and troughed at $79.1 million in Q3 2024.
• A 5-year average of $91.1 million and a median of $90.5 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses climbed 27.55% in 2022, then plunged 30.43% in 2024.
• Over 5 years, Operating Expenses stood at $94.4 million in 2022, then grew by 23.8% to $116.9 million in 2023, then slumped by 30.43% to $81.3 million in 2024, then climbed by 3.88% to $84.5 million in 2025, then climbed by 6.66% to $90.1 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $90.1 million, $84.5 million, and $83.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.